Long-term safety of adalimumab in clinical trials in adult patients with Crohn’s disease or ulcerative colitis.

Long-term safety of adalimumab in clinical trials in adult patients with Crohn’s disease or ulcerative colitis. Aliment Pharmacol Ther. 2017 Nov 21;: Authors: Colombel JF, Sandborn WJ, Reinisch W, Peyrin-Biroulet L, Panaccione R, Rutgeerts P, Hanauer SB, Ghosh S, Van Assche G, Robinson AM, Lau W, Maa JF, Huang B, Pappalardo B, Read H Abstract BACKGROUND: Adalimumab is used to treat moderate to severe Crohn’s disease (CD) and ulcerative colitis (UC) when conventional therapies fail. AIM: To update long-term adalimumab safety from CD and UC trials; the previous report was…

Read More

Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.

Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy. Aliment Pharmacol Ther. 2017 Nov 09;: Authors: Bar-Yoseph H, Levhar N, Selinger L, Manor U, Yavzori M, Picard O, Fudim E, Kopylov U, Eliakim R, Ben-Horin S, Chowers Y, Ungar B Abstract BACKGROUND: Primary nonresponse, defined as lack of clinical benefit during the induction phase, occurs in up to 30% of IBD patients treated with infliximab. The mechanisms underlying primary nonresponse have not yet been clearly defined. AIM: To evaluate the association of early (week 2…

Read More

Exploration of predictive biomarkers of early infliximab response in acute severe colitis: A prospective pilot study.

Exploration of predictive biomarkers of early infliximab response in acute severe colitis: A prospective pilot study. J Crohns Colitis. 2017 Nov 07;: Authors: Beswick L, Rosella O, Rosella G, Headon B, Sparrow MP, Gibson PR, van Langenberg DR Abstract Background: Outcomes of acute severe ulcerative colitis (ASUC) appear dependent on early intervention with the first and/or further infliximab(IFX) doses, though parameters to guide decision-making remain uncertain. Aim: To assess whether serum/faecal IFX levels and inflammatory biomarkers early post-IFX dose can predict ASUC outcomes. Methods: This prospective pilot study consecutively recruited…

Read More

Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.

Related Articles Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. JAMA. 2017 Nov 07;318(17):1679-1686 Authors: Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, Dray-Spira R Abstract Importance: An increased risk of lymphoma has been reported among patients receiving thiopurines for inflammatory bowel disease (IBD). The risk of lymphoma associated with anti-tumor necrosis factor (TNF) agents either alone or in combination with thiopurines is uncertain. Objective: To assess the risk of…

Read More

Yes, We Are Still Talking about Cylosporin vs. Infliximab in Steroid Resistant Acute Severe Ulcerative Colitis.

Related Articles Yes, We Are Still Talking about Cylosporin vs. Infliximab in Steroid Resistant Acute Severe Ulcerative Colitis. Am J Gastroenterol. 2017 Nov;112(11):1719-1721 Authors: Bernstein CN, Kornbluth A Abstract The Spanish IBD Registry (ENEIDA) is reporting in this issue of the Journal on a retrospective assessment of outcomes of cyclosporine use and infliximab use to treat steroid refractory acute severe ulcerative colitis (SR-ASUC) between 1989 and 2013. Overall, they found similar outcomes in terms of 3 month and 1 year colectomy rates. Serious adverse events were lower in cyclosporine users….

Read More

The risk of non-melanoma skin cancer in New Zealand in Inflammatory Bowel Disease patients treated with thiopurines.

Related Articles The risk of non-melanoma skin cancer in New Zealand in Inflammatory Bowel Disease patients treated with thiopurines. J Gastroenterol Hepatol. 2017 Nov 04;: Authors: Bahi M, Walmsley RS, Gray AR, Young D, Hobbs CE, Aluzaite K, Schultz M Abstract BACKGROUND AND AIM: New Zealand (NZ) has one of the highest rates of non-melanoma skin cancers (NMSC) in the world. Thiopurine use in Inflammatory Bowel Disease (IBD) patients has been shown to increase NMSC risk. This study aimed to investigate the possible increase of NMSC risk in thiopurine-treated IBD…

Read More

Clinical and pharmacokinetic factors associated with adalimumab-induced mucosal healing in patients with Crohn’s disease.

Related Articles Clinical and pharmacokinetic factors associated with adalimumab-induced mucosal healing in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2017 Nov 02;: Authors: Watanabe K, Matsumoto T, Hisamatsu T, Nakase H, Motoya S, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T, DIAMOND study group Abstract BACKGROUND & AIMS: We previously reported results from a prospective randomized controlled trial comparing the efficacy of adalimumab monotherapy vs combination with azathioprine for patients with Crohn’s…

Read More

Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study.

Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study. World J Gastroenterol. 2017 Oct 21;23(39):7139-7149 Authors: Luchetti MM, Benfaremo D, Ciccia F, Bolognini L, Ciferri M, Farinelli A, Rossini M, Mosca P, Triolo G, Gabrielli A Abstract AIM: To report adalimumab (Ada) efficacy on articular-gastrointestinal disease and health-related quality of life (HRQoL) in patients with enteropathic spondyloarthritis (ES). METHODS: A cohort of 52 patients with ES was evaluated in the departments of gastroenterology and internal medicine. At baseline, all patients underwent assessment by an integrated gastro-rheumatologic evaluation of articular…

Read More

Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn’s disease.

Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn’s disease. J Gastroenterol Hepatol. 2017 Oct 31;: Authors: Tanaka H, Kamata N, Yamada A, Endo K, Fujii T, Yoshino T, Sugaya T, Yokoyama Y, Bamba S, Umeno J, Yanai Y, Ishii M, Kawaguchi T, Shinzaki S, Toya Y, Kobayashi T, Nojima M, Hibi T, ADJUST study group Abstract BACKGROUND AND AIM: There are few studies on the long-term efficacy of adalimumab treatment for patients with Crohn’s disease. We have conducted a large, multicenter, retrospective cohort study…

Read More

Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology.

Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology. World J Gastroenterol. 2017 Sep 28;23(36):6628-6638 Authors: Dubois-Camacho K, Ottum PA, Franco-Muñoz D, De la Fuente M, Torres-Riquelme A, Díaz-Jiménez D, Olivares-Morales M, Astudillo G, Quera R, Hermoso MA Abstract Inflammatory bowel diseases (IBDs), such as ulcerative colitis and Crohn’s disease, are chronic pathologies associated with a deregulated immune response in the intestinal mucosa, and they are triggered by environmental factors in genetically susceptible individuals. Exogenous glucocorticoids (GCs) are widely used as anti-inflammatory therapy in IBDs. In the…

Read More
<< Go Back